The American College of Physicians has become the latest organization to weigh in on the controversial subject of PSA screening for prostate cancer.
Older men with metastatic castration-resistant prostate cancer (CRPC) derive a similar if not superior survival benefit from treatment with enzalutamide (Xtandi) as do younger men, according to a post-hoc analysis of the phase III AFFIRM trial.
Eighteen years of follow-up of the Prostate Cancer Prevention Trial (PCPT) suggests that 7 years of treatment with the 5-alpha-reductase inhibitor finasteride (Proscar) for prostate cancer prevention does not appear to affect mortality but does reduce the risk of a prostate cancer diagnosis.
Increased adoption of the practice of obtaining 10- to 12-core biopsy specimens of the prostate has resulted in increased detection of prostate cancer across the United States, a recent large study shows.
Since the days of the digitally directed prostate nodule biopsy using the Vim-Silverman needle, the optimum prostate biopsy strategy has evolved.
Anticoagulation while on docetaxel (Taxotere) chemotherapy appears to be an independent predictor of survival in men with metastatic castration-resistant prostate cancer (mCRPC).